Licensing

Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System

January 18, 2018

NEW YORK, Jan. 17, 2018 /PRNewswire/ — Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that it has acquired the global rights to develop and market dextromethadone (REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, for the treatment of neurological conditions including […]

Brazilian Health Surveillance Agency, ANVISA, Adopts Certara’s Phoenix Software for Drug Regulatory Reviews

January 17, 2018

Phoenix will help to increase productivity, improve management workflows, and ensure high accuracy for pharmacokinetic/pharmacodynamic and toxicokinetic studies Certara®, the global leader in model-informed drug development and regulatory science, today announced that the Brazilian National Health Surveillance Agency – ANVISA (Agência Nacional de Vigilância Sanitária) – is now also employing Certara’s Phoenix® WinNonlin® software for […]

Marina Biotech Announces Agreement for Drug Development and Licensing with Autotelic Bio

January 16, 2018

City of Industry, CA, Jan. 16, 2018 (GLOBE NEWSWIRE) — Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, announced today that the Company has entered into a binding agreement with Autotelic Bio Inc., to enter into a license of Marina’s […]

Nuvo Pharmaceuticals (Ireland) Limited Acquires U.S. Product Rights to Resultz® from Piedmont Pharmaceuticals LLC

January 15, 2018

MISSISSAUGA, ON, Jan. 15, 2018 /PRNewswire/ – Nuvo Pharmaceuticals Inc.™ (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) Limited (Nuvo Ireland) has acquired the U.S. rights to Resultz® (50% isopropyl myristate, […]

Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals

January 11, 2018

SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken™, OmniRat®, OmniMouse® and OmniFlic® to discover fully human mono- and multispecific antibodies. Ligand is eligible to receive annual platform access […]

Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific

January 10, 2018

Basel, Switzerland, January 10, 2018 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today the completion of its extension of its license agreement with Pfizer Inc. (NYSE: PFE) for Basilea’s antifungal Cresemba® (isavuconazole) to include China (with Hong Kong and Macao) and sixteen countries in the Asia Pacific region, execution of which was announced on December […]

Teva Announces Global License Agreement with Alder BioPharmaceuticals® in the Field of Anti-CGRP-Based Therapy

January 9, 2018

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that its subsidiary, Teva Pharmaceuticals International GmbH., has signed a global license agreement with Alder BioPharmaceuticals. The agreement validates Teva’s IP and resolves Alder’s opposition to Teva’s European Patent No. 1957106 B1, with respect to anti-calcitonin gene-related peptide (CGRP) antibodies and methods for their use. […]

Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies

January 9, 2018

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ: EXEL) today announced that it has entered into an exclusive collaboration and license agreement with StemSynergy Therapeutics, Inc., (StemSynergy) for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1α), a component of the Wnt signaling pathway implicated in key oncogenic processes. The agreement […]

Appili Therapeutics Licenses Bioterrorism Vaccine Rights

January 9, 2018

HALIFAX, Nova Scotia–(BUSINESS WIRE)–Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, announced today it has signed a licence agreement with the National Research Council of Canada (NRC) to develop ATI-1701, a vaccine to protect against Francisella tularensis, a potential bioterrorism agent that causes tularemia.   “It is very rewarding to see […]

Exelixis and StemSynergy Enter into Exclusive Licensing Agreement for the Discovery and Development of Novel Anticancer Therapies

January 8, 2018

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Exelixis, Inc. (NASDAQ: EXEL) today announced that it has entered into an exclusive collaboration and license agreement with StemSynergy Therapeutics, Inc., (StemSynergy) for the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha (CK1α), a component of the Wnt signaling pathway implicated in key oncogenic processes. The […]

Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug Discovery

January 8, 2018

SHANGHAI & ROTTERDAM, The Netherlands & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Harbour BioMed announced today that it has licensed its patented H2L2 transgenic mouse platform for generating fully human therapeutic monoclonal antibodies to BeiGene, Ltd. (NASDAQ: BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The […]

Acerus Enters into a Licensing Agreement with Innovus to Commercialize UriVarx® in Canada

January 8, 2018

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has entered into an exclusive distributor and license agreement with Innovus Pharmaceuticals, Inc. (OTCQB: INNV) (“Innovus”), a California-based specialty pharmaceutical company developing safe and effective over-the-counter medicines, granting Acerus the exclusive rights to commercialize UriVarx® in Canada.   “We are confident that […]

Innovus Pharma Enters Into License and Distribution Agreement with Acerus Pharmaceuticals for the Commercialization of UriVarx® in Canada

January 8, 2018

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today announced that […]

Cypralis and Gilead Sciences, Inc. agree on license terms under which Cypralis will hold exclusive development and commercialisation rights to certain jointly-owned ‘cyprolides’ for acute and chronic degenerative diseases

January 8, 2018

Cambridge, UK, 8th January 2017 / Sciad Newswire / Cypralis and Gilead Sciences, Inc. (“Gilead”) have agreed that Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology. This is a further step in the collaboration between the parties which follows […]

BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region

January 8, 2018

CAMBRIDGE, Mass. and BEIJING, China and SAN DIEGO, Jan. 08, 2018 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, and Mirati Therapeutics (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced an exclusive license agreement for the development, […]

TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies

January 8, 2018

NEW YORK and SHANGHAI, China, Jan. 08, 2018 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ:TGTX) (or “TG”) and Jiangsu Hengrui Medicine Co., Ltd. (SSE:600276) (or “Hengrui”) today announced that the companies have entered into an exclusive global license agreement pursuant to which TG Therapeutics will obtain worldwide rights, excluding Asia but including Japan, for the […]

Pierre Fabre Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Selective Potassium Channel Blocker for Atrial Fibrillation

January 5, 2018

CASTRES, France & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Pierre Fabre Pharmaceuticals (Pierre Fabre) and Boston Pharmaceuticals Inc. (Boston Pharmaceuticals) today announced they have entered into a worldwide licensing agreement for Pierre Fabre’s selective potassium channel blocker, F17727.   “While our R&D and commercial focus has shifted away from cardiology, we are committed to ensuring that promising compounds are […]

Distributed Bio Announces SuperHuman Platform License Agreement With Pfizer Inc.

January 5, 2018

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce an agreement with Pfizer Inc. (NYSE: PFE) to license the Distributed Bio SuperHuman Platform for the identification of novel antibodies for use as therapeutic agents.   Distributed Bio licenses SuperHuman antibody discovery platform […]

Ablexis Announces Licensing of the AlivaMab Mouse to NGM Biopharmaceuticals

January 5, 2018

BURLINGAME, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) — Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with NGM Biopharmaceuticals, Inc. The non-exclusive license grants NGM rights to use the AlivaMab Mouse for antibody drug discovery and development. “Ablexis is pleased to add […]

Nuevolution to Receive License Fee Payment of USD 750,000

January 4, 2018

STOCKHOLM, Jan. 4, 2018 /PRNewswire/ — Nuevolution AB (publ) (NUE.ST) today announced that Janssen Biotech, one of the Pharmaceutical Companies of Johnson & Johnson, has exercised its option to license one of the research programs under the multi-target collaboration entered between the parties in October 2015 – a collaboration that was expanded further in April […]

Pierre Fabre Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Selective Potassium Channel Blocker for Atrial Fibrillation

January 4, 2018

CASTRES, France, CAMBRIDGE, Mass. – January 4, 2018 – Pierre Fabre Pharmaceuticals (Pierre Fabre) and Boston Pharmaceuticals Inc. (Boston Pharmaceuticals) today announced they have entered into a worldwide licensing agreement for Pierre Fabre’s selective potassium channel blocker, F17727. F17727 is a small molecule in late preclinical development for the potential treatment of atrial fibrillation (AF). […]

PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® (plitidepsin) with Megapharm in Israel

January 3, 2018

MADRID, January 2, 2018 /PRNewswire/ —   PharmaMar (MCE:PHM) has announced today a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority.   (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b ) According to the agreement Megapharm will register Aplidin® on behalf of PharmaMar and […]

Generex Confirms Receipt of $700,000 USD License Fee from Shenzhen BioScien Pharmaceuticals

January 3, 2018

MIRAMAR, Fla.–(BUSINESS WIRE)–Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today confirmed its receipt of the $700,000 USD up-front license fee (net of applicable Chinese withholding taxes) payable by Shenzhen BioScien Pharmaceuticals Co. Ltd. (www.BioScien.cn) under the License and Research Agreement entered into with Generex wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com). The purpose of the Agreement is […]

Orbis Biosciences Announces Licensing Agreement with Reckitt Benckiser

January 3, 2018

LENEXA, Kan., Jan. 3, 2018 /PRNewswire/ — Orbis Biosciences, Inc. announced today that it has entered into an exclusive global license agreement leveraging its Precision Particle Fabrication® technology. Reckitt Benckiser (RB), world leading Consumer Healthcare company, and Orbis have entered into an exclusive cooperation agreement to develop and commercialize novel technologies in the field of […]

Orbis Biosciences Announces Licensing Agreement with Reckitt Benckiser

January 3, 2018

LENEXA, Kan., Jan. 3, 2018 /PRNewswire/ — Orbis Biosciences, Inc. announced today that it has entered into an exclusive global license agreement leveraging its Precision Particle Fabrication® technology. Reckitt Benckiser (RB), world leading Consumer Healthcare company, and Orbis have entered into an exclusive cooperation agreement to develop and commercialize novel technologies in the field of […]

Albireo Announces Royalty Monetization Agreement with HealthCare Royalty Partners for Elobixibat in Japan

January 3, 2018

BOSTON, Jan. 03, 2018 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that subsidiary Elobix AB has entered into an agreement with HealthCare Royalty Partners (HCR) to monetize its royalty rights under its license agreement with EA Pharma Co., Ltd. for elobixibat […]

Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China

January 2, 2018

PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV), within Greater China (China, Hong Kong, Macao, Taiwan). […]

vTv Therapeutics Announces Licensing Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co. to Rights for vTv’s GLP-1r Agonist Diabetes Program in China and Other Pacific Rim Territories

December 21, 2017

HIGH POINT, N.C.–(BUSINESS WIRE)–vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong Pharmaceutical”), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZSE: 000963.SZ), for rights to develop and commercialize vTv Therapeutics’ GLP-1r agonist program in China and other Pacific Rim […]

Summit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI

December 21, 2017

OXFORD, United Kingdom, Dec. 21, 2017 (GLOBE NEWSWIRE) — Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection (‘CDI’), announces that it has entered into an exclusive licence and commercialisation agreement granting Eurofarma Laboratórios SA (‘Eurofarma’) rights in Latin America (the ‘Licensed Territory’) […]

FEEDBACK